Fig. 4

b-AP15 inhibits the migration of SU-DHL-4 and SU-DHL-2 cells through decreasingWNT and TGFβ canonical pathways. (a) SU-DHL-4 and SU-DHL-2 cells were dose dependently treated with b-AP15. The number of migration cells were decreased according to the raising doses. Mean ± SD (n = 3). * P < 0.05, **P < 0.01, ***P < 0.001 (b) WNT canonical pathway related proteins were analyzed by Western blot. Representative images were shown. (c) TGFβ canonical pathway related proteins were analyzed by Western blot. Representative images were shown. (d) The protein levels of β-catenin and c-Mycwere detected by Western blot with SKL2001(20 μM), IWR-1-endo(20 μM), or b-AP15(0.025 μM for SU-DHL-4 cellsand 0.075 μM for SU-DHL-2 cells) treatment over 24 h.Representative images were shown. (e) The cell migration assays were performed after SKL2001(20 μM), IWR-1-endo (20 μM) or b-AP15 incubated 24 h.Mean ± SD (n = 3). * P < 0.05, **P < 0.01, ***P < 0.001 (f) The protein level of p-Smad2/3 and Smad2/3 were detected by Western blot with 10 ng/ml rhTGFβ1, TP0427735 HCl (20 μM), SIS3 HCl (20 μM) or b-AP15 treatment over 24 h. Representative images were shown. (g) The cell migration was detected after treatment with TP0427735 HCl (20 μM), SIS HCl (20 μM) or b-AP15 over 24 h. Mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.0001, versus control group